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Polymorphonuclear neutrophils in Wegener’s granulomatosis The etiology and pathogenesis of Wegener’s granulo-
acquire characteristics of antigen presenting cells. matosis is still elusive. Autoimmune phenomena, most
Background. Constitutive expression of major histocompat- probably in response to infectious agents, have been dis-ibility complex (MHC) class II antigens and of the co-stimula-
cussed as the initiating event [1, 2]. There is ample evi-tory receptors CD80 and CD86 is restricted to professional anti-
dence for activation of the immune system, includinggen presenting cells. Polymorphonuclear neutrophils (PMN)
of healthy donors are negative for those antigens. Our recent activation of T lymphocytes [3–7], autoantibody forma-
study, however, found that PMN of patients with active Wege- tion, particularly to polymorphonuclear neutrophil (PMN)-
ner’s granulomatosis acquired MHC class II antigens. derived cytoplasmic antigens (ANCA) [reviewed in 8–10],Methods. To continue and extend the previous study results,
and for cytokine production [11, 12]. Also, the effector cellsPMN and monocytes of 60 patients with Wegener’s granuloma-
are activated, and enhanced cytokine production by mono-tosis, 24 patients with microscopic polyangiitis (MPA), 20 pa-
tients with acute bacterial infection, and 53 healthy donors cytes has been reported [13], as well as increased adhe-
were analyzed for the expression of MHC class II antigens as sion of PMN [14]. Moreover, studies with isolated PMN
well as of CD80 and CD86. Moreover, induction on PMN of showed activation by ANCA [15–18]. How these eventsMHC class II expression was studied, as was antigen presenta-
are related to each other and how they contribute to thetion as a possible functional consequence.
pathogenesis of the disease is still under investigation.Results. PMN of patients with acute, active Wegener’s gran-
ulomatosis expressed MHC class II antigens, CD80 and CD86; We recently described expression of major histocom-
on monocytes up-regulation of MHC class II was seen. In con- patibility complex (MHC) class II antigens on PMN of pa-
trast, PMN of patients with inactive disease, or with relapse, pa- tients with clinically active Wegener’s granulomatosis [19].tients with microscopic polyangiitis or with bacterial infections
This finding was of particular interest, because MHCexpressed neither MHC class II, nor CD80 or CD86. PMN of
healthy donors acquired these antigens when cultured in the class II antigens are normally found only on professional
presence of T cells or T cell-derived cytokines. The PMN were antigen presenting cells, such as dendritic cells, B cells,
then able to present to T cell antigens in a MHC-class II re- monocytes, or macrophages, but not on PMN of healthy
stricted manner.
donors. Since the only known function of MHC class IIConclusion. During active disease, the PMN of patients with
molecules is the presentation to T cells of antigens, ourWegener’s granulomatosis acquire characteristics of antigen
presenting cells, whereas the PMN of patients with MPA or data provided first evidence that under pathological con-
bacterial infection do not. The finding reflects differences in ditions PMN might acquire the capacity to function as
the pattern of the respective inflammatory response and sug- accessory cells for T cell activation.
gests new effector functions of PMN. Moreover, MHC class
Our current study addressed the question of whetherII expression on PMN could serve as a novel marker for active
MHC class II expression was characteristic for Wege-Wegener’s granulomatosis.
ner’s granulomatosis or whether it also occurred in pa-
tients with microscopic polyangiitis; moreover, we tested
whether PMN acquired CD80 and CD86 (also known
as B7.1 and B7.2). As co-stimulatory molecules, both
CD80 and CD86 bind to CD28, one of the most relevant
signal-transducing events in T cell activation [20, 21].Key words: primary vasculitis, ANCA-associated vasculitis, PMN,
MHC class II antigens, antigen presentation. The consequence of MHC class II expression on PMN
was tested with PMN of healthy donors. We found thatReceived for publication May 9, 2001
PMN were able to present to T-cell superantigens andand in revised form July 6, 2001
Accepted for publication July 23, 2001 peptide antigens, and that they induced T cell prolifera-
tion in a MHC class II-restricted manner. 2001 by the International Society of Nephrology
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METHODS crescentic glomerulonephritis and in two patients mesan-
gioproliferative GN was seen; (g) nervous system in-Patients
volvement included seizures, mononeuritis multiplex or
After approval by the Ethikkommission (Ethics com- peripheral neuropathy; (h) heart, involvement comprised
mittee) of the University Heidelberg Hospital and after pericarditis, myocardial infarction or cardiomyopathy.
having obtained informed consent, patients with Wege- Data of patients with Wegener’s granulomatosis gath-
ner’s granulomatosis or microscopic polyangiitis (MPA) ered between September 1996 and April 1998 were al-
attending the renal unit of the Heidelberg University ready published [19]. In the present study, only patients
Hospital were included in a prospective study. Wegener’s attending the renal unit between December 1998 and
granulomatosis was diagnosed according to the defi- June 2000 were considered.
nition of the Chapel Hill conference [22] and to the The following groups of patients were formed ac-
American College of Rheumatology (ACR) criteria [23]. cording to the clinical presentation of patients with Weg-
Disease activity was determined by the “Birmingham ener’s granulomatosis: patients with newly diagnosed
Vasculitis Activity Score” (BVAS) [24]. In all patients, systemic active disease (BVAS 1; N  10); patients
ANCA titers (normal value 1:20), proteinase 3 (PR3)- developing a relapse under immunosuppressive therapy
ANCA (10%) and myeloperoxidase (MPO)-ANCA (N  5); patients with inactive disease (BVAS 1 or 0)
(2 U) were measured as reported elsewhere [25, 26]. under immunosuppressive therapy (N  25); and pa-
Laboratory tests were performed by routine methods tients with inactive disease and receiving no immuno-
(Hitachi autoanalyzer; Hitachi, Tokyo, Japan; blood cell suppressive therapy (N  20; Table 1).
counts by Coulter counter; Coulter Electronics, Hialeah, Microscopic polyangiitis (MPA) was defined by the
FL, USA). Urine analysis was done by test strips (Com- presence of necrotizing crescentic glomerulonephritis as-
bur 8 test kit; Boehringer Mannheim, Mannheim, Ger- sociated with extrarenal vasculitis involving small ves-
many), by Addis Count and by measurement of 24-hour sels. None of the patients had asthma or granuloma for-
protein excretion with Biuret; urinary sediment was ana- mation. Pulmonary manifestation was dominated by lung
lyzed by phase contrast microscopy. hemorrhage with characteristic chest radiographs. There
Patients with vasculitis and additional complications were no nodules or cavitations. Patients with upper respi-
including acute infections as detected by x-ray, blood ratory tract involvement were not considered to have
cultures, antiviral IgM titers or by measuring procalcito- Wegener’s granulomatosis when there was no evidence
nin levels1 ng/mL [27] were excluded, as were patients for granulomatous infection or invasive bony disease.
with chronic inflammatory disease (cholecystolithiasis, Most patients had radiographic features of sinusitis. The
inflammatory bowel disease, bronchitis, osteomyelitis), upper respiratory involvement was generally mild as de-
patients with kidney transplants or patients on dialysis. scribed also by others [22, 28]. All patients seen between
The first patients entered the study in September 1996; September 1996 and January 2000 were included, and
the study was closed in June 2000. Only patients with as described for patients with Wegener’s granulomatosis,
systemic disease and more than two organ involvement grouped according to the clinical presentation when they
were included in the study. Many patients were seen re- were first seen. Nine patients with newly diagnosed MPA
peatedly, usually in 8- to 12-week intervals, or when the are included in the study, as well as two patients devel-
disease became active again or other complications arose. oping relapses under immunosuppressive therapy, and
Data on patients and clinical findings are summarized in 16 patients with inactive disease (Table 1).
Table 1. In short, the following criteria were used to de- Immunosuppressive therapy in patients with Wege-
fine organ involvement: (a) skin, such as palpable pur- ner’s granulomatosis and MPA consisted of a combina-
pura, ulcers or nodules; (b) musculoskeletal, such as ar- tion of methylprednisolone, cyclophosphamide or aza-
thralgias, arthritis or polymyalgia; (c) eyes, such as (epi-) thioprine.
scleritis, keratitis, uveitis or retinal vasculitis; (d) ear/ Patients with acute bacterial infections. For compari-
nose/throat (ENT), such as nasal mucosal ulceration with son, twenty patients (recruited from January to Septem-
or without epistaxis, otitis media, sinusitis or tracheal ber 1999) with acute bacterial infections, but no symp-
stenosis; (e) lower respiratory tract (lung), such as hemo- toms of autoimmune or chronic inflammatory disease,
ptysis, alveolar hemorrhage, respiratory failure, asthma, were included in the study. Diagnosis was based on bac-
coin lesions or radiographic proof of pulmonary infil- terial culture, high plasma levels of C reactive protein
trates in the absence of infectious etiology; ( f) kidney, (8 mg/L), leukocytosis (10  103/L), procalcitonin
where renal involvement was defined as elevated serum levels higher 1 ng/mL, and fever.
creatinine, decreased creatinine clearance, microscopic Healthy individuals. For comparison, PMN of healthy
hematuria (5 red blood cells per high power field) individuals, comparable with regard to age and sex were
and/or red cell casts and/or proteinuria (0.3 g/dL); the analyzed. Twenty-five donors were tested within the same
time as the patients with Wegener’s granulomatosis, 28majority of patients had biopsy-proven pauci-immune
Iking-Konert et al: MHCII, CD80 and CD86 2249
Table 1. Laboratory findings and clinical characteristics of all patients participating in the study
Patients with Wegener’s granulomatosis
Patients with MPAActive disease Inactive disease
under under
immuno- immuno- Active disease Inactive disease
Active disease suppressive suppressive Inactive disease Active disease relapse under with and w/o
no therapy therapy therapy no therapy no therapy therapy therapy
Total number of patients 10 5 25 20 9 2 10
BVASa
Range 3–20 5–10 0–1 0 11–15 0 0
Mean 10.85.3 7.32.5 0.2 12.91.4
Median 10 7 0 12
Age 23–73 41–70 23–73 28–80 22–77 57–76 22–80
Sex 3 male 2 male 11 male 6 male 7 male 1 male 8 male
CRP mg/L
Range 3.3–240 3.3–58 3.3–22 3.3–14 3.3–216 3.2–69 3.2–44
Mean 94.278 21.922.2 6.04.8 4.02.4 78.179.4 36.232.9 9.714.7
Leukocyte 10 3/lL
Range 5.66–11.4 1.8–15.5 3.8–12.7 4.21–11.0 3.93–16.5 5.79–10.5 3.6–17.9
Mean 10.42.2 9.65.5 7.82.99 6.31.4 9.673.8 8.22.36 7.572.9
ANCA (1:20) 10/10b 4/5 21/25 8/20 9/9 2/2 6/16
(100%) (80%) (84%) (40%) (100%) (100%) (25%)
PR3 (10%) 9/10 2/5 11/25 3/20 0 0 0
(88.9%) (40%) (44%) (15%)
MPO (2 U/mL) 1/10 0 0 1/20 7/9c 1/2 7/14
(11.1%) (5%) (77.8%) (50%) (50%)
Organ involvement
Kidney 7 4 17 18 9 2 16
(77.8%) (80%) (89.5%) (90.0%) (100%) (100%) (100%)
Ear/nose/throat 8 4 14 14 1 1 4
(80%) (80%) (73.7%) (70%) (11.1%) (50%) (25%)
Lung 3 3 8 8 0 1 3
(33.3%) (60%) (42.1%) (40%) (50.0%) (15.7%)
Skin 2 1 4 2 0 1 2
(22.2%) (20%) (21.1%) (10%) (50.0%) (12.5%)
Nervous system 3 1 6 3 0 0 4
(33.3%) (20%) (31.6%) (15%) (25%)
Muscles 4 4 8 6 4 1 10
(44.4%) (44.4%) (42.1%) (30%) (44.4%) (50.0%) (62.5%)
Eyes 4 3 7 9 3 0 4
(44.4%) (60%) (28%) (45%) (33.3%) (25%)
Heart 0 1 2 1 0 0 2
(20%) (10.5%) (5%) (12.5%)
a BVAS, Birmingham vasculitis activity score [24]
b One patient had antibodies to pANCA and MPO (patient #6), but not to cANCA and PR3
c One patient had antibodies to pANCA, lactoferrin (125, normal 5) and low titer of anti-MPO (3.9 U/mL, normal 2 U/mL) (patient #57)
during the time the MPA study was performed. The two described previously no major changes were observed
within that time [19]. Results are expressed as % CD66bcontrol groups were not different from each other.
positive PMN or as mean fluorescence units (MFI) for
Determination of surface antigen expression monocytes. Normal values were established from analyz-
by cytofluorometry ing 53 healthy donors. The 90% percentile was set as
threshold and values higher than 5.5% for MHC classThe respective surface molecules were detected by
double-labeling with fluorescein (FITC)-conjugated an- II; 5% for CD80; 12% for CD86; and 12% for CD64
were considered positive. For cytofluorometry of iso-tibody to CD66b as marker for PMN, CD14 as marker
for monocytes and phycoerythrin (PE)-conjugated anti- lated PMN 5  105 to 1  106 cells were suspended in
phosphate-buffered saline (PBS) containing 1% bovinebodies to MHC class II (anti-DP, -DQ, -DR; Serotec,
purchased from Biozol, Eching, Germany), CD80 and serum albumin (BSA) and 0.1% Na-azide and incubated
with the respective antibodies as described above.CD86 (Serotec). For comparison, isotype-matched mouse
IgGs (Serotec) were used in comparable protein concen-
Statistical analysistrations. To avoid changes in surface expression due to
handling procedures, antibody-labeling was performed The results for MHC Class II, CD80 and CD86, and
CD64 are presented as box blots, with the box containingin whole blood within two hours after withdrawal. As
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50% of the values. The highest, lowest and the median gous monocytes and B cells. The procedure was repeated
after 15 days. Then the cells were sub-cloned (100 cells/values are depicted. Differences between the patients’
group and the healthy controls were analyzed using the well) and cells with high proliferation rate for elastase
in the presence of autologous mononuclear cells, and noWilcoxon test. Patients with bacterial infections (N 
20) were considered as a separate group. reactivity with other antigens (tetanus toxoid, TT) or
mononuclear cells alone were chosen for further propa-
Isolation of polymorphonuclear neutrophils and gation. After two more rounds of re-stimulation and sub-
of T cells cloning, two lines (ELA5 and ELA10) were used for the
experiments. Moreover, one T cell line with reactivityFrom peripheral blood of healthy donors or of selected
patients mononuclear cells and PMN were separated by for TT (FRIT-T), established previously [29] and two
T cell lines with reactivity for Staphylococcus enterotoxincentrifugation on PolymorphPrep (Nycomed, Oslo, Nor-
way). For the functional experiments (antigen presenta- E (SEE); A37/2 and D894, established and given to us
by D. Kabelitz) were used [30].tion) and the reverse transcription-polymerase chain re-
action (RT-PCR) the PMN fraction was further purified
T cell proliferation testby adsorption to CD15-beads by magnetic cell separation
(autoMACS) using the devices supplied by MiltenyBio- Purified PMN (1  105), B cells or monocytes were
added to each well of a 96-well flat bottom plate. B cellstech (Bergisch-Gladbach, Germany). As judged by cyto-
fluorometry with antibodies to CD66b/CD18 as a marker were irradiated with 80 grays, monocytes with 60 grays,
respectively. Then, 1  105 T-cells and elastase (0.2 g/for PMN, the purity was greater than 99%. From the
mononuclear cell fraction, T cells were further purified well), TT (0.2 g/well; Calbiochem, La Jolla, CA, USA),
or SEE (2 ng/well; Serva), respectively, were added.by adsorption to anti-CD3, B cells by anti-CD19 and
monocytes by absorption to anti-CD14 using autoMACS After co-incubation for four days at 37C with 5% CO2,
cells were pulsed by adding 1 Ci of 3H-thymidine (spe-(MylteniBiotech). The procedure yielded highly homog-
enous preparations as seen by cytofluorometry. cific activity 5 Ci/mmol; Amersham Life Science, Braun-
schweig, Germany) to each well and harvested 14 to 16
Cultivation of PMN hours later. 3H-thymidine incorporation into DNA was
To induce MHC class II surface expression purified measured with a scintillation counter (Packard, Gron-
PMN (1106/mL) were cultivated in AIM V (Gibco, Eg- ingen, Netherlands) and expressed as counts per minute
genstein, Germany) with 2.5% autologous serum (NHS), (cpm). The values represent the mean  SD of 6 to 12
granulocyte macrophage-colony stimulating factor (GM- parallel wells. In some experiments, nonadherent cells
CSF) 50 U/mL and interferon gamma (IFN-) 100 U/mL were harvested after four days, and pulsed with 3H-thy-
(Sigma) for the times indicated. Survival of PMN in midine for 14 to 16 hours. An aliquot of those cells was
culture was measured by propidium iodide staining and subjected to cytofluorometry and identified as T cells by
only experiments with more than 80% PMN surviving the use of an anti-CD3 (95% CD3 positive cells). For
were considered reliable [29]. For cultivation of whole inhibition experiments, monoclonal antibodies (mAbs)
blood, samples were collected in heparin-coated tubes against intercellular adhesion molecule-1 (ICAM-1),
(Sarstedt, Nu¨rmbrecht, Germany); portions of 1 mL CD80, CD86, and MHC II were used in concentrations
were incubated with the cytokines in the concentrations of 1 g/mL (0.2 g/well). IgG1, IgG2a and IgG2b were
and for the times indicated. Erythrocytes were lysed used as isotype controls in the same final concentration.
before analyzing surface expression of the respective Antibodies were added together with the antigens and
antigens as described above. were present throughout the entire incubation time.
Determination of MHC class II specific RNA. RNA
was isolated from PMN using a commercially available
RESULTSkit (Roche, Mannheim, Germany). MHC class II-specific
Polymorphonuclear neutrophils of patients with activeRNA and for comparison 	 actin-specific RNA were
Wegener’s granulomatosis are phenotypically alteredamplified by RT-PCR as described in the study of Rad-
when compared to the PMN of healthy donors. By cyto-sak et al [29].
fluorometry, using forward/side scatter analysis, a sub-
T cell lines population of PMN (5 to 20%) was seen that appeared
larger and more granular. Moreover, the PMN expressedT cell lines with specificity for elastase were estab-
MHC class II antigens, CD80 and CD86, with the alteredlished from a healthy donor. Isolated T cells were culti-
PMN being more positive. After immunosuppressivevated with autologous monocytes and B cells and 5 g
therapy, the morphological changes as well as the expres-heat-inactivated elastase (Calbiochem, Darmstadt, Ger-
sion of MHC class II, CD80 and CD86 decreased [anmany). After five days in culture, T cells were separated
and again cultivated with elastase and irradiated autolo- example is shown in Fig. 1]. Alteration of PMN morphol-
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Fig. 1. Analysis of polymorphonuclear neutrophils (PMN) of a patient with active Wegener’s granulomatosis by flow cytofluorometry. (A) To
100 L heparinized blood, FITC-labeled antibodies to CD66b (as a marker for PMN) together with PE-labeled antibodies were added to HLA-DP,
HLA-DQ, HLA-DR, CD80, or CD86. Then the cells were analyzed by cytofluorometry. At least 12,000 events were counted. The forward-side
scatter analysis (left panel), revealed two major PMN populations (identified by anti-CD66b), termed R1 (84% of total PMN) and R2 (16% of
total PMN), monocytes (R3) and lymphocytes (R4). The PMN of both R1 and R2 expressed HLA-DP, HLA-DQ, HLA-DR, CD80, and CD86
as measured by double-labeling cytofluorometry (right panels). The population in R2 contained more positive PMN with higher expression of the
respective antigens. (B) The same experimental set up with blood of the same patients ten days after starting the immunosuppressive therapy.
The cells in R2 had declined to 2% of total PMN count. (C ) The analysis of blood of a healthy donor. Only 0.2% of PMN were detected in the
area of R2.
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Table 2. MHC class II, CD80, CD86 and CD64 expression on PMN of patients with Wegener’s granulomatosis, MPA and healthy donors
Patients with Wegener’s granulomatosis
Active disease Inactive disease
Active disease immunosuppres- immunosuppres- Inactive disease
no therapy sive therapy sive therapy no therapy Healthy donors
MHC class II-positive PMN 9/10a 0/5 6/25 8/20 3/25
(5.5% of PMN) 90% 0 24% 45% 12%
CD80 positive PMN 6/10a 0/5 4/25b 1/20 3/25
(5%) 60% 0 17.4% 5% 12%
CD86 positive PMN 8/8b 0.2b 7/18b 8/16b 3/25
(12%) 100% 0 38.9% 50% 12%
CD64 positive PMN 3/5b 5/5 10/11b 8/12b 1/15b
(12%) 60% 100% 90.9% 66.6% 6.6%
Patients with microscopic polyangiitis (MPA)
Active disease Active disease Inactive disease
no therapy relapse under therapy w and w/o therapy Healthy donorsc
MHC class II-positive PMN 2/9 0/2 0/16 1/28
(5.5%) 22.2% 0 0 3.5%
CD64 positive PMN 7/7b 2/2 4/16 3/28
(12%) 100% 100% 25% 10.7%
a PMN of one patient (patient #6) were completely negative for MHC class II; this patient had pANCA and antibodies to MPO (13.2)
b Data were not available for all patients
c Different group as for Wegener’s granulomatosis
ogy and expression of MHC class II, CD80 and CD86 The CD86 expression on PMN correlated to some
extent with the MHC class II expression (R 0.7). Otherwas seen in 9 of 10 patients with active Wegener’s granu-
lomatosis (Table 2). The patient, who did not express linear correlation, for example, of MHC class II and
CD80 surface expression, or abundance of either MHCMHC class II nor CD80 or CD86 had pANCA (titer
1:80) and antibodies to MPO (13.2; normal value 2) II, CD80, CD86 and autoantibody titers were not found.
CD64 was expressed on the PMN of Wegener patients.but not to PR3. By nasal biopsy, however, granuloma
was detected, leading to the diagnosis of Wegener’s gran- The expression, however, did not differ between patients
with active disease or patients with inactive disease, butulomatosis.
In patients with clinically inactive disease, with or with- was different from that of healthy donors (Fig. 2).
Twenty-four patients with MPA were analyzed (Ta-out immunosuppressive therapy, only low levels of MHC
class II or CD80 expression were seen in a few patients. ble 1). In two of the nine patients with active disease,
minor MHC class II expression (7.4% and 6.45%, respec-Expression was significantly lower than in patients with
active disease (largest P value 2.4  10
4 for MHC class tively) on PMN was seen. When analyzed as a group,
there was no difference between patients with activeII, and 0.002 for CD80) and was not different from
healthy controls. PMN of patients with relapse under disease, inactive disease or healthy controls (Fig. 2). The
same observation was made for CD80 and CD86 expres-immunosuppressive therapy did not express MHC class
II nor CD80 (Table 2 and Fig. 2). sion. None of the patients developing a relapse expressed
MHC class II, CD80 or CD86 on PMN. In all patientsHigh expression of CD86 was seen on PMN of patients
with Wegener’s granulomatosis irrespective of disease with active disease, however, up-regulation of CD64 was
seen (Fig. 2 and Table 2).activity, but was not found on PMN of healthy donors
(largest P value 0.016). Though the median value for As an example for acute inflammatory disease, pa-
tients with bacterial infections were included in the study.CD86 expression was higher on PMN of patients with
active disease than that for patients with inactive disease, Neither MHC class II antigens nor CD80 were found.
CD86 was only mildly enhanced in some patients. Thethe groups did not differ from each other due to the
large variations (Fig. 2). The follow-up studies of single median values for MHC class II, CD80 and CD86 expres-
sion did not differ from that of healthy controls. Thepatients, however, showed that expression of CD86 de-
clined rapidly under immunosuppressive therapy as did PMN, however, expressed high levels of CD64, indicat-
ing activation (Fig. 2).expression of MHC class II and of CD80 (Fig. 1A, data
of five patients are summarized in Table 3). In parallel, In addition to PMN, monocytes were analyzed with
regard to MHC class II expression. Monocytes of healthythe abundance of MHC class II-specific mRNA declined,
consistent with the fact that MHC class II antigens are donors express MHC class II molecules. From 40 healthy
donors a median value for the mean fluorescence of 112synthesized de novo (Fig. 1B).
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Fig. 2. Expression of major histocompatibility complex (MHC) class II, CD80, CD86 and CD64 on PMN of patients with Wegener’s granulomatosis,
microscopic polyangiitis (MPA) or bacterial infections. Expression was measured as % positive PMN. Box blots are shown for each surface antigen.
The boxes contain 50% of the values. The highest, lowest and median values are shown for: Wegener patients with active disease without therapy
(active, N 10) patients suffering a relapse under immunosuppressive therapy (relapse N 5), patients with inactive disease and immunosuppressive
therapy (N  25), patients with inactive disease and no therapy (N  20), healthy donors (N  25), patients with MPA and active disease (active,
N  9), with inactive disease (N  16) and healthy donors (N  28), and patients with bacterial infections (acute, N  20). For MHC class II
and CD80 expression the superscript symbol (*) indicates that the respective group differed from all the others (P  0.001 for MHC class II and
P  0.01 for CD80); (#) the value for patient 6 with pANCA and MPO antibodies. CD86 expression was significantly enhanced in all patients
with Wegener’s granulomatosis (*largest P  0.016), as was CD64 (*largest P  0.006). In patients with MPA, CD64 expression was higher in
patients with active disease than in patients with inactive disease or healthy donors (**P  0.02 and 1.2  10
6, respectively). PMN of patients
with bacterial infections (N  20) did not express MHC class II, CD80 or CD86. Only expression of CD64 differed form that of the healthy donors
(***largest P  3.3  10
6).
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Table 3. Follow-up study in five patients entering the study with active systemic disease of Wegener’s granulomatosis
(BVAS 1) and receiving immunosuppressive therapy
% positive PMN
cANCA MHC II on
Patient Date BVAS PR3 MHC II CD80 CD86 monocytes (MFI)
1 1.7.99 10 1:80 20.9 10 15.8 93
41.4
27.7.99 0 1:40 2.4 1.6 5.5 72.8
therapy 8.4
11.8.99 0 1:49 2.5 3.6 3.3 92
therapy 0
2 5.3.99 6 1:80 58.9 9.6 41.5 385
25.8
16.3.99 0 1:80 2.4 0.3 51 248
therapy 9.1
3 17.2.99 16 1:1280 22.9 2.5 13.5 462
54.4
30.4.99 0 1:80 1.36 3.2 3.9 168
therapy 22.7
17.6.99 0 1:80 1.5 0.74 6.7 186
therapy 10.5
30.7.99 0 1:40 2.3 0.9 not done 180
therapy 12.6
4 24.6.99 17 1:640 10.8 5.1 33.6 77
24.2
27.7.99 0 0.45 0.89 1.8 60
therapy
5a 16.3.99 10 5.7 1.9 16.8 234
23.4.99 0 1.1 0.6 3.85 63
therapy
19.7.99 5 0.8 1.5 5.2 106
relapse w therapy
2.8.99 8 7.8 10.7 6.6 128
10.10.99 4 1.3 0.9 2.4 60
therapy
a Patient with relapse under immunosuppressive therapy and uncertain compliance.
MFI was determined. Many, but not all, patients with derived from healthy donors. When PMN were co-culti-
vated with autologous T cells and MHC class II expres-Wegener’s granulomatosis showed enhanced levels of
MHC class II expression on monocytes. The median sion, the expression of CD80 and CD86 increased within
24 to 72 hours (Fig. 4 and Table 4). Essentially similarvalue for patients with active disease, however, was not
statistically different from that of patients with inactive results were obtained when PMN were cultivated with
heterologous T cells or cells of the various T cell lines.disease (Fig. 3). Expression of MHC class II on mono-
cytes determined as MFI did not correlate linearly to As described previously, culture of PMN with either
T cell supernatants or INF- alone or in combinationMHC class II on PMN (R  0.45), however, monocytes
of patients with MHC class II-positive PMN (5.5%) with GM-CSF induced synthesis and surface expression
of MHC class II [29]. Following culture, the PMN showedexpressed significantly more MHC class II than patients
with MHC class II-negative PMN (Fig. 3). Follow-up a similar shift in the forward-side scatter analysis as the
PMN derived from the patients with active Wegener’sstudies with single patients showed that, together with
MHC class II expression on PMN, the MFI of monocytes granulomatosis, and again, similarly to the in vivo obser-
vation, the shifted PMN expressed more of MHC classdeclined (Table 3). On monocytes of patients with active
MPA no up-regulation of MHC class II was detectable II per cell than PMN in the original position (Fig. 5; c.f.
Fig. 1).(data not shown).
Various questions arose from the in vivo observations. In addition to IFN- and GM-CSF, a number of other
cytokines including interleukin (IL)-2, IL-4, IL-6, andThe two most pertinent questions were how PMN are
activated to acquire MHC class II, CD80 and CD86, IL-8, G-CSF and tumor necrosis factor- (TNF-) were
tested for their ability to induce MHC class II expression.and what would be the functional consequences of this
activation. None of the cytokines either alone or in combination
had effects on MHC class II expression.In that respect, induction of MHC class II expression
on PMN of healthy donors was tested. A first set of To mimic the in vivo situation closer, a second set
of experiments tested the induction of MHC class IIexperiments was performed with highly purified PMN
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Fig. 3. Expression of MHC class II antigens on monocytes. (A) Box blots show the expression of MHC class II (measured as MFI) of the patients
with Wegener’s granulomatosis (c.f. Fig. 2) and of healthy donors. The patient groups were not different from each other, but all differed from
the healthy donors (largest P value 0.005). (B) MHC class II expression on PMN did not correlate linearly with MHC class II expression on
monocytes (insert); patients, however, with PMN expressing MHC class II (5.5% positive PMN) had significantly higher MHC class expression
also on monocytes.
synthesis on PMN in whole blood. Again samples of whole blood of patients under immunosuppressive ther-
apy with steroids was cultivated for 24 to 72 hours indifferent healthy donors blood were used and it was seen
that IFN- and GM-CSF increased the levels of MHC the presence of IFN- and GM-CSF. At all times the
MHC class II surface expression was considerably lessclass II expression from 2.8  1.4% in freshly drawn
blood to 25.5  15.5% after 24 hours and 33.9  8.7% when compared to the PMN of patients with Wegener’s
disease in remission without therapy or to the PMN ofpositive PMN after 48 hours (N  7; Fig. 6).
Data with cultivated PMN of healthy donors had pro- healthy donors (Fig. 6).
While the data support the hypothesis that T cells orvided evidence that acquisition of MHC class II, CD80
and CD86 depended on de novo protein synthesis, as it T cell-derived cytokines such as IFN- or GM-CSF in-
duce MHC class II expression on PMN, the presence ofcould be inhibited by cycloheximide [29]. Apparently,
also in vivo, those antigens are produced by de novo those cytokines in patients’ sera could not be demon-
strated unequivocally. IFN- was only found in thesynthesis, since specific RNA was found in patients with
active disease only, but not in patients with immunosup- plasma of two of 12 patients with active Wegener’s gran-
ulomatosis and GM-CSF in four other patients.pressive therapy or in healthy donors (Fig. 7).
The observation that MHC class II expression de- Since the only known function of MHC class II anti-
gens is the presentation of peptide antigens to T cells,creased rapidly in patients undergoing immunosuppres-
sive therapy suggests that steroids might prevent up-regu- we tested whether MHC class II-positive PMN were able
to function as accessory cells for T cell activation in anlation of MHC class II in vivo. To test that assumption,
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Fig. 4. Induction of MHC class II expression on PMN by co-culture with T cells. Highly purified PMN (106) were co-cultivated with T-cells (106)
for 48 hours. By forward-side scatter analysis the two cell population can be easily distinguished and identified as PMN (R1) or T cells (R2) by
the use of monoclonal antibodies. When setting the gate around the PMN population, it can be seen that a portion of PMN had acquired MHC
class II, and CD86 (filled peaks; the lines show the respective isotype controls).
antigen-dependent, MHC class II-restricted manner. In
a first set of experiments, MHC class II-positive PMNTable 4. Induction of MHC class II, CD80 and CD86 synthesis on
PMN after co-culture with autologous T cells and T cells derived from patients with active Wegener’s
disease (N  3) were co-cultivated with or without anti-Percent expression of
Number of gen. A high proliferation rate of T cells was seen, regard-Time in culture MHC class II CD80 CD86 experiments
less of the presence of antigen or of PMN of monocytes,
Before culture 0–5% 0–5.5% 0–7% 12
respectively. Since the T cells of healthy donors either24 hours 5–12% 2–18% 6–24% 5
48 hours 5–24% 6–20% 15–30% 6 do not or only to a minor degree do proliferate without
72 hours 5–25% 5–19% 18–35% 3 antigens or mitogens, the data are indicative of a pro-
Iking-Konert et al: MHCII, CD80 and CD86 2257
Fig. 5. Induction of MHC class II antigens on PMN. PMN from a healthy donor were cultivated in the presence of IFN- (100 U/mL) and
GM-CSF (50 U/mL) for 48 hours. The forward-side scatter analysis revealed several changes of the original (O) PMN population. A portion of
the PMN were dead or dying. In R4 mainly cellular debris is seen in R3 apoptotic cells as judged by propidium iodide (PI) exclusion. In addition
to the viable cells in R2 (R2 corresponds roughly to the original position) an additional population was seen (R1) comprising 15% of cells in R2.
PMN in R1 and R2 expressed MHC class II, in contrast to PMN before culture. The binding of IgG, not shown here, was not altered when the
three cell populations were compared.
found T cell activation in vivo (data not shown). Since be induced, while heterologous PMN failed to induce T
cell proliferation (data for 2 elastase-specific lines, ELA5these findings precluded the use of patient-derived cells
for the in vitro studies, the following experiments were and ELA10, and for one TT-specific line, FRIT-T are
summarized in Table 5). Of note was that proliferationcarried out with PMN of healthy donors, induced to
express MHC class II, CD80 and CD86 by INF- and of the elastase-specific T cells also occurred without the
addition of elastase, whereas proliferation of the TT-GM-CSF for 24 hours. The proliferative response of
autologous, peripheral T cells was tested with two differ- specific T cell line required TT. An essentially similar
pattern of T cell activation was observed when mono-ent peptide antigens, tetanus toxoid (TT) and elastase.
With either elastase or TT only a minor, but statistically cytes were used in place of PMN. On the other hand,
with B cells as with antigen-presenting cells, proliferationsignificant T cell proliferation was seen (Table 4). To
enhance the frequency of antigen-specific T cells, lines depended on the addition of elastase (Table 5). Though
PMN are considered to be non-dividing cells, an experi-with reactivity for either elastase or TT were established
from a healthy donor. With the respective antigens and ment was performed where the non-adherent cells were
harvested after four days of culture. Then, 3H-thymidineautologous PMN considerable T cell proliferation could
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Fig. 6. Induction of MHC class II antigens
on PMN of donors or patients in whole blood.
In blood samples of patients with Wegener’s
granulomatosis under immunosuppressive ther-
apy (N  11), without therapy (N  5) or of
healthy donors (N  7) MHC class II expres-
sion was measured by cytofluorometry imme-
diately after withdrawal of blood and again 48
hours after incubation with IFN- (100 U/mL)
and GM-CSF (50 U/mL). Before culture ()
MHC class II antigen was not expressed; fol-
lowing culture ( ) the PMN acquired MHC
class II (largest P value 0.001); PMN of pa-
tients without therapy or of healthy controls
acquired significantly more MHC class II anti-
gens than PMN of patients under immunosup-
pressive therapy.
was added to the remaining cell layer and as well as to There is ample evidence for PMN activation during
the harvested cells. Incorporation of 3H-thymidine was active disease: massive infiltration of PMN into glomeruli
only seen in the non-adherent cells that were identified and small vessels of the interstitium was described; gen-
as T cells by cytofluorometry. eration of PMN-derived oxygen radicals and lysosomal
With either T cell line, PMN-induced proliferation enzyme release were detected in correlation to disease
could be inhibited by antibodies to either MHC class II activity [16]. Activation might be due to cytokines, espe-
(anti-DR; 40%) or to ICAM-1 (65%). cially to IL-8, which is found in inflammatory lesions
Since previous data by others described the relevance [33]. Moreover, in vitro data show that PMN can be
of Staphylococcus aureus-derived superantigens (SE) in activated by ANCA [9, 15, 18, 34]. Our data imply that
relapses of Wegener’s granulomatosis, we tested whether T cell-derived mediators, such as interferon-, are deci-
MHC class II-positive PMN of either patients with Weg- sive for PMN activation in vasculitis. We found recently
ener’s granulomatosis (in relapse and without immuno- that PMN of patients with Wegener’s granulomatosis
suppressive therapy) or of healthy donors would present acquired MHC class II antigens when the disease was
SE and induce T cell proliferation. In both cases prolifer- active [19]. MHC class II antigens are synthesized de
ation of T cells was found, dependent on MHC class II novo upon stimulation of PMN with interferon- or
and ICAM-1 (Table 6). GM-CSF [29, 35] and, as shown in the present study,
also by direct contact with T cells.
In the presence of interferon- PMN escape—at leastDISCUSSION
temporarily—their constitutive apoptosis [36, 37]. In ad-In the course of ANCA-positive vasculitis the immune
dition to MHC class II they acquire CD80 and CD86system is activated as seen by the up-regulation of recep-
[29], and they assume new functions, particularly super-tors on immunocompetent cells, enhanced cytokine lev-
antigen and antigen presentation [29, 37, 38], the latterels and production of autoantibodies [3–14, 31]. The con-
being critically dependent on the presence of the co-tributions of the respective activities to the pathogenesis
stimulatory properties of CD80 and CD86.of vasculitis are under intense investigation, and while a
Owing to the significance of CD80 and CD86, ourcorrelation to disease activity has been found particularly
previous study [19] was extended to test for the presencefor autoantibody generation, a causal relationship has
not yet been established [8–10, 32]. of the co-stimulatory antigens CD80 and CD86 on PMN.
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and without immunosuppressive therapy, some MHC
class II, CD80 or CD86 expression was seen, suggesting
low-level T cell activity. The assumption is supported by
the observation that CD25-positive T cells are found
also in patients with clinically inactive disease [3]. The
fact that MHC class II was not elevated in patients with
a relapse under immunosuppressive therapy is in line
with the in vitro findings that PMN derived from patients
under immunosuppressive therapy expressed consider-
ably less MHC class II antigens than PMN of healthy
donors or of patients without therapy. That a relapse of
disease occurs without up-regulation of MHC class II
does not rule out a role for class II-positive PMN in the
pathogenesis of the disease, but makes participation in
the early events rather unlikely.
Polymorphonuclear neutrophils of patients with MPA
were not morphologically altered. Only 2 of the 11 pa-
tients with active disease showed minor MHC class II
expression on PMN and no enhanced expression on
monocytes. However, CD64, the high affinity receptor
for IgG, was up-regulated in patients with active disease,
indicating PMN activation. A similar observation was
made with PMN of patients with acute bacterial infec-
tion: up-regulation of CD64 was observed, but not MHC
class II (Fig. 2). The data indicate that induction of MHC
class II expression and CD64 up-regulation are regulatedFig. 7. Detection of MHC class II by RT-PCR in PMN of a patient
independently of each other.with active Wegener’s granulomatosis. In PMN of a patient with active
disease, with MHC II specific primer pairs a PCR products was found The activation pattern of PMN occurring in active
(lane 1), which could not be detected 10 days after onset of immunosup- Wegener’s granulomatosis resembled that of PMN de-pressive therapy (lane 2). Lane 3 shows the MHC class II PCR product
rived from healthy donors cultivated with T cell-derivedof IFN- (100 U/mL) treated PMN. M is the size marker.
mediators or T cells. Considering the presence of acti-
vated T cell in patients with active disease, T cells are
the most likely source of those cytokines in vivo. The
Moreover, patients with MPA were included. The pa- assumption is supported by the observation that mono-
tients with Wegener’s granulomatosis presented more cytes are activated to express more MHC class II anti-
severe impairment of renal function than the patients gens. T cell-derived mediators, particularly IFN-, have
with MPA. The patients with MPA had less extrarenal long been known to affect monocyte MHC class II ex-
involvement when compared to patients with Wegener’s pression [40]. The failure to detect the cytokines in the
granulomatosis, an observation made before by others plasma of patients with active disease does not rule out
[15, 39]. The activity score (BVAS), however, did not that possibility, since cytokines are rapidly bound to their
differ significantly between the two groups of patients respective target cells or to extracellular matrix proteins,
(Table 1). PMN of patients with active Wegener’s granu- and soluble circulating mediators usually reflect only the
lomatosis displayed an impressive morphological change surplus. Thus, it is reasonable to assume that in vivo
and expressed MHC class II, CD80 and CD86 in close PMN are activated as consequence of a T cell response.
correlation to disease activity (Fig. 1). There was only The most obvious alterations of PMN, extended life-
one exception: PMN of patient #6 did not acquire MHC span and MHC class II, CD80 and CD86 expression,
class II, CD80 or CD86 (Table 1). That patient had could contribute to the inflammatory process, because
pANCA and antibodies to MPO, but not to PR3. Never- (1) escape from apoptosis is thought to be a decisive
theless, the detection of localized granuloma lead to the factor of the inflammatory response [41], and (2) MHC
diagnosis of Wegener’s granulomatosis. class II bearing PMN could present antigen to T cells,
Under immunosuppressive therapy, PMN resumed and initiate or sustain an antigen-specific T cell response.
their normal morphological appearance, and expression In support of a role of PMN in the induction of a
of MHC class II, CD80 and CD86 declined, being in specific immune response, we found that PMN were able
line with the concept that T cell-derived mediators are to present antigens in a MHC class II-restricted manner.
Since the high proliferation rate of T-lymphocytes de-involved. In some patients with clinically inactive disease
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Table 5. Proliferation of peripheral T cells or antigen-specific T cell lines in response to antigen presented by PMN, monocytes or B cells
Antigen presenting cells Proliferation cpm
10 5 Antigen (meanSD of at least N6) Comments
Peripheral T cells (105) cultivated with
Autologous PMN Elastase 2355288a a Different from ‘no antigen’ (P0.05)
Autologous PMN TT 2973507a
Autologous PMN No antigen 1595235
Heterologous PMN Elastase 1090267 Values are not different from each other
Heterologous PMN TT 1230345
Heterologous PMN No antigen 1056202
T cell line ELA-5 cultivated with
Autologous PMN Elastase 9739840a a Different from ‘no antigen’ (P0.01)
Autologous PMN No antigen 2324256aa aa Different from ‘no antigen, no PMN’ (P0.05)
No PMN No antigen 1125210
Heterologous PMN Elastase 1230510 Values are not different from ‘no antigen, no PMN’
Heterologous PMN No antigen 1389379
Autologous monocytes Elastase 98901020b b Different from to ‘no antigen’ (P0.01)
Autologous monocytes No antigen 3590466bb bb Different from ‘no antigen, no PMN’ (P0.05)
Heterologous monocytes Elastase 98059 Not different from ‘no antigen, no PMN’
Heterologous monocytes No antigen 1289369
Autologous B cells Elastase 123092358a a Different from ‘no antigen’ (P0.005)
Autologous B cells No antigen 43891290
No cells Elastase 16001267
T cell line ELA-10 cultivated with
Autologous PMN Elastase 143792690a a Not different from each other, but from values
Autologous PMN No antigen 117793870a obtained with ‘no PMN, no antigen’ or with
heterologous PMN (largest P0.0012)
No PMN No antigen 2500890
Heterologous PMN Elastase 1468238 Not different from ‘no PMN, no antigen’
Heterologous PMN No antigen 23891279
Autologous monocytes Elastase 97001345b b Not different from each other, but from values
Autologous monocytes No antigen 107892389b obtained with heterologous monocytes
(P0.005)
Heterologous monocytes Elastase 28791008
Heterologous monocytes No antigen 35451230
Autologous B cells Elastase 145823467a a Different from ‘no antigen’ (P0.05)
Autologous B cells No antigen 56002899
No cells Elastase 34581266
T cell line FRIT-T cultivated with
Autologous PMN TT 123892370a a Different from ‘no antigen,’ ‘no PMN, no antigen,’
and ‘heterologous PMN’ (largest P0.0018)
Autologous PMN No antigen 23671199
No PMN No antigen 2000897
Heterologous PMN TT 20071234b b Not different from ‘no antigen’ or ‘no PMN,
No antigen’
Heterologous PMN No antigen 34581898
Autologous monocytes TT 256982599b b Different from ‘no antigen’
Autologous monocytes No antigen 2569990
Autologous B cells TT 324884510c c Different from ‘no antigen’
Autologous B cells No antigen 56992800
No cells TT 1344580
Differences between values were calculated by the t test for two populations.
rived from patients with active Wegener’s granulomato- of exogenously added elastase. One interpretation is that
endogenous elastase, which is released from PMN orsis precluded the use of those PMN for in vitro experi-
ments, cells of healthy donors, which are known to monocytes upon activation, is sufficiently abundant to
serve as the antigen. The presumption is supported byacquire MHC class II upon stimulation, were used. Pe-
ripheral T cells proliferated only to a minor degree when the fact that B cells, which do not express elastase, in-
duced T cell proliferation only when elastase was added.co-cultivated with PMN or monocytes and TT or elastase
as antigens, being in line with a low frequency of antigen- Because of the notion that the presence of Staphylo-
coccus enterotoxin coincides with relapses of Wegener’sspecific precursor cells. With established, antigen-specific
T cell lines, in contrast, considerable T cell proliferation granulomatosis [2], we tested whether PMN was able to
also present Staph enterotoxin. Staph enterotoxin is acould be induced provided autologous PMN were used.
Of special note was that the elastase-specific clones also superantigen, so-called because it binds outside of the
peptide-binding groove of the MHC class II and thewere activated by PMN and monocytes in the absence
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Table 6. Proliferation of T cells and T cell lines in response to Staphylococcus enterotoxin E (SEE) presented by PMN or monocytes
Proliferation
Peripheral T cells (10 5) incubated with SEE cpm; meanSD; N12 Comments
PMN (105) a Values different from all the others,
SEE 2 ng 803455689 largest P1.210
5
SEE 0.2 ng 752306712
SEE 0.02 ng 456124002
No SEE 25771300a
PMN (105) b Values different from IgG control
SEE 0.2 ng IgG 347893980 (P0.01)
anti-MHC II 178442005b
anti-ICAM-1 98701256b
Monocytes (105)
SEE 2 ng 1208778700
SEE 0.2 ng 13850012098
SEE 0.02 ng 967338761
No SEE 34712199
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